Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Mario19860 Jan. 14 at 8:18 PM

$JSPR

1 · Reply

MikiTrader Jan. 13 at 8:43 PM

$JSPR Bottom line, I didn’t buy it

0 · Reply

kim14e Jan. 13 at 9:54 AM

$JSPR Short borrow fee is too cheap

0 · Reply

Drosendale88 Jan. 12 at 8:30 PM

$JSPR took a pretty good arsekicking, I think it’ll limp back to $1.80-$2.00 by eom once sellers leave and buyers stop the jitters

0 · Reply

hitmongreen Jan. 12 at 8:14 PM

$JSPR yikes mate?

0 · Reply

Biotech41 Jan. 12 at 8:04 PM

$JSPR Where will this stop??

0 · Reply

FIREINSP Jan. 12 at 1:24 PM

$JSPR This gets sold off today by me. I will take the loss. Absolute garbage...

0 · Reply

kim14e Jan. 12 at 4:05 AM

$JSPR goes to 7

2 · Reply

BinaryLogic Jan. 11 at 12:31 PM

$JSPR The Company has tremendous upside long-term (IMO); however, transient liquidity issues [$50M Cash/ST against $(75)M TTM burn rate] show a runway less than 12mos. A new CEO appointment might drive the case for an alternative (partnership) or further dilution alternatively to preserve liquidity. The stock is still not Oversold on either the 1YR or 3YR charts, so investors might want to wait here for clarity on the liquidity position, a dramatic (further) fallout or otherwise. Long term multiplier upside from this level $1.5 (IMO) with further success on Beacon study. https://www.stocktitan.net/news/JSPR/jasper-therapeutics-reports-positive-updated-data-from-briquilimab-m31w8t9icy1z.html

1 · Reply

Drosendale88 Jan. 9 at 6:29 PM

$JSPR this dipped the moment SCOTUS tariff ruling delay and I don’t even know why, it should affect you in no meaningful way lol

0 · Reply

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jan 8, 2026, 7:00 AM EST - 6 days ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 7, 2026, 4:30 PM EST - 7 days ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Dec 2, 2025, 5:53 PM EST - 6 weeks ago

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript

Dec 2, 2025, 7:00 AM EST - 6 weeks ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 6 weeks ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 7 weeks ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 2 months ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 2 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 2 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 4 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 4 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 4 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 5 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 6 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 6 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 6 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 7 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 8 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 11 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 11 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 11 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 11 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Mario19860 Jan. 14 at 8:18 PM

$JSPR

1 · Reply

MikiTrader Jan. 13 at 8:43 PM

$JSPR Bottom line, I didn’t buy it

0 · Reply

kim14e Jan. 13 at 9:54 AM

$JSPR Short borrow fee is too cheap

0 · Reply

Drosendale88 Jan. 12 at 8:30 PM

$JSPR took a pretty good arsekicking, I think it’ll limp back to $1.80-$2.00 by eom once sellers leave and buyers stop the jitters

0 · Reply

hitmongreen Jan. 12 at 8:14 PM

$JSPR yikes mate?

0 · Reply

Biotech41 Jan. 12 at 8:04 PM

$JSPR Where will this stop??

0 · Reply

FIREINSP Jan. 12 at 1:24 PM

$JSPR This gets sold off today by me. I will take the loss. Absolute garbage...

0 · Reply

kim14e Jan. 12 at 4:05 AM

$JSPR goes to 7

2 · Reply

BinaryLogic Jan. 11 at 12:31 PM

1 · Reply

Drosendale88 Jan. 9 at 6:29 PM

$JSPR this dipped the moment SCOTUS tariff ruling delay and I don’t even know why, it should affect you in no meaningful way lol

0 · Reply

FIREINSP Jan. 9 at 6:03 PM

$JSPR

0 · Reply

LORAXX Jan. 9 at 3:00 PM

$JSPR News was good. Approx. 78% of float owned by tutes with 5 million shares left to trade. Could get interesting especially if partnership announced.

0 · Reply

BioTechChap Jan. 9 at 1:13 PM

$JSPR Fair summary - R.B.C. analyst: "Overall, we continue to think briq is likely comparably active to key competitors (though not being clearly better makes optics challenging), and may have safety advantages. However, we think shares may remain rangebound given the timeline gap and capital constraints, which may make it more challenging to convince investors that briq's potential differentiation will be meaningful."

2 · Reply

Mario19860 Jan. 9 at 10:04 AM

$JSPR here is biggest problem money...

0 · Reply

lowriskdailycompounder Jan. 8 at 9:42 PM

$JSPR

0 · Reply

fasteddiecakes Jan. 8 at 8:15 PM

$JSPR could they be diluting on the good news? Just a thought.

0 · Reply

jn_svoboda Jan. 8 at 6:54 PM

$JSPR Sell this crap! Totally untrustworthy.

0 · Reply

Bullshyte Jan. 8 at 6:52 PM

$JSPR Can anyone sensibly, please explain why this stop has taken such a beating today when they reported positive news at the beginning of the day...!?

1 · Reply

wilberth92 Jan. 8 at 6:50 PM

$JSPR

1 · Reply

afonso_of_wall_street Jan. 8 at 6:35 PM

$JSPR All news outlets saying good data and stock drops? Seems like a good add on the dip

0 · Reply

afonso_of_wall_street Jan. 8 at 6:27 PM

$JSPR Why fall if good data?

0 · Reply

Stmkr Jan. 8 at 4:30 PM

$JSPR Time to admit defeat here...

0 · Reply

Market Cap	41.42M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	822,700
Avg Vol	2,052,270
Day's Range	N/A - N/A
Shares Out	27.98M
Stochastic %K	32%
Beta	3.07
Analysts	Strong Sell
Price Target	$12.67